Traders should monitor Unbuzzd sales velocity and marketing traction as a proxy for Quantum BioPharma’s potential royalty inflows and valuation re-rating. A successful commercial ramp could justify a higher multiple on QNTM given its small $9M market cap and retained economic interests.
Price Chart
Executive Summary
Quantum BioPharma announced the peer-reviewed publication of a clinical trial showing its dietary supplement 'unbuzzd' significantly accelerated alcohol metabolism, reduced intoxication symptoms, and alleviated hangovers with no reported side effects. The study, published in a scientific journal, supports the product's efficacy and may enhance credibility among consumers and investors. Quantum BioPharma retains a 19.86% stake in Unbuzzd Wellness Inc. and is entitled to royalties on sales up to $250 million.
Key Facts
- Clinical trial of 'unbuzzd' published in peer-reviewed journal World Journal of Pharmaceutical and Medical Research (2026, vol 12, issue 3, pp 446–467).
- unbuzzd reduced blood alcohol concentration (BAC) more than 40% faster within 30 minutes vs. placebo, with continued acceleration over 4 hours.
- Statistically significant improvements in alertness, heart rate stabilization, perceived impairment, and hangover symptoms (67% reduction in headache severity at 4 hours).
- No adverse side effects reported in trial participants.
- Quantum BioPharma owns 19.86% of Unbuzzd Wellness Inc. (as of Sept 30, 2025) and receives 7% royalty on sales until $250M total payments, then 3% in perpetuity.
- unbuzzd is available via www.unbuzzd.com and Amazon; product is a dietary supplement, not a pharmaceutical.
Financial Impact
Potential royalty stream up to $250 million at 7%, then 3% in perpetuity; indirect revenue upside via equity stake in Unbuzzd Wellness Inc.
Risk Factors
- unbuzzd is a dietary supplement, not FDA-approved; limited regulatory protection or pricing power.
- Revenue dependent on third-party (Unbuzzd Wellness Inc.) commercial execution.
- Market skepticism around clinical relevance of BAC reduction without behavioral or legal endorsement (e.g., not for driving).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260361 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.33 (−25.08%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.33 (−24.60%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.33 (−24.60%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.33 (−28.75%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.33 (−41.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.33 (−37.37%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.33 (−37.37%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.33 (−32.66%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.33 (−24.35%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.33 (−24.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers